Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SHR9549
i
Other names:
SHR9549
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Jiangsu Hengrui Pharma
Drug class:
Selective estrogen receptor degrader
Related drugs:
‹
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
AZD9833 (7)
LY3484356 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
AZD9833 (7)
LY3484356 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
GDC-0927 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
›
Associations
News
Trials
Filter by
Latest
2years
SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov)
P1, N=4, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=44 --> 4 | Unknown status --> Terminated; Sponsor R & D Strategy Adjustment
2 years ago
Enrollment change • Trial termination
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
SHR9549
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login